Multi-drug resistant tuberculosis: Experiences of two tertiary referral centres

Irish Medical Journal

Volumn 104, Issue 6, 2011, Pages

  Kennedy, B ^a   O'Connor, B ^a   Korn, B ^b   Gibbons, N ^b   O'Connor, T ^a   Keane, J ^b  

^a MERCY UNIVERSITY HOSPITAL   (Ireland)

^b ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CAPREOMYCIN; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; KANAMYCIN; PASINIAZID; PROTIONAMIDE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; AGED; ARTICLE; AZERBAIJAN; BACTERIUM CULTURE; BACTERIUM ISOLATE; CAUCASIAN; CLINICAL ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DRUG EFFICACY; ETHNICITY; FEMALE; GASTROINTESTINAL SYMPTOM; HEARING LOSS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRELAND; LITHUANIA; LUNG TUBERCULOSIS; MALE; MEDICAL AUDIT; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; OTOTOXICITY; RURAL AREA; SIDE EFFECT; SOUTH AFRICA; SPUTUM CULTURE; SPUTUM EXAMINATION; TERTIARY HEALTH CARE; TREATMENT DURATION; TREATMENT OUTCOME; URBAN AREA; ZAMBIA; CLINICAL TRIAL; INCIDENCE; MIDDLE AGED; MULTICENTER STUDY; MULTIDRUG RESISTANCE; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE; FEMALE; HUMANS; INCIDENCE; IRELAND; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 79960611547     PISSN: 03323102     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. American Thoracic Society; CDC; Infectious Diseases Society of America. Treatment of tuberculosis. MMWR Recomm Rep. 2003 Jun 20;52:1-77.
2. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One. 2009 Sep 9;4:e6914.
3. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med. 1993 Feb 25;328:527-532.
4. Gandhi NR, Shah NS, Andrews JR, Vella V, Moll AP, Scott M, Weissman D, Marra C, Lalloo UG, Friedland GH. HIV Co-infection in Multidrug-and Extensively Drug-resistant Tuberculosis Results in High Early Mortality. Am J Respir Crit Care Med 2010; 181: 80-86.
5. Min SM, Kelly P, Byrne C, Clancy L. Antibiotic resistant tuberculosis and bovine tuberculosis in an Irish hospital population (1991 to 2001). Ir Med J. 2005 Feb;98:38-40.
6. Health Protection Surveillance Centre. HIV & AIDS, to end 2010 [www.hpsc.ie]. [updated 2010 June 18; cited 2010 August 26]. Available from http://www.hpsc.ie/hpsc/AZ/HepatitisHIVAIDSandSTIs/HIVandAIDS/SurveillanceReports/File,3781,en.pdf.
7. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis [www.who.int]. [updated 2006; cited 2010 August 26]. Available from http://whqlibdoc.who.int/publications/2006/9241546956_eng.pdf.
8. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, Zarovska E, Rich ML, Fraser HS, Alarcn E, Cegielski JP, Grzemska M, Gupta R, Espinal M. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005 Jun;9:640-645.
9. Brummett RE, Fox KE. Aminoglycoside-induced hearing loss in humans. Antimicrob Agents Chemother. 1989 Jun;33:797-800.
10. World Health Organisation. Global tuberculosis control: epidemiology, strategy, financing: WHO report 2009 (Publication no. WHO/HTM/TB/2009.411.). [www.who.it]. [updated 2009; cited 2010 August 26]. Available from http://www.who.int/tb/publications/global_report/2009/pdf/full_report.pdf.
11. Report on the Epidemiology of Tuberculosis in Ireland 2006 [cited 2010 August 26].Available from http://www.hpsc.ie/hpsc/A-Z/VaccinePreventable/TuberculosisTB/Publications/AnnualReportsontheEpidemiologyofTBinIreland/File,3374,en.pdf.
12. Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, Hoffner S, Drobniewski F, Barrera L, van Soolingen D, Boulabhal F, Paramasivan CN, Kam KM, Mitarai S, Nunn P, Raviglione M; Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet. 2009 May 30;373:1861-1873.
13. Annual Reports on the Epidemiology of Tuberculosis in Ireland [cited 26 August 2010]. Available from http://www.hpsc.ie/hpsc/A-Z/VaccinePreventable/TuberculosisTB/Publications/AnnualReportsontheEpidemiologyofTBinIreland/
14. Wells CD, Cegielski JP, Nelson LJ, Laserson KF, Holtz TH, Finlay A, Castro KG, Weyer K. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis. 2007 Aug 15;196 Suppl 1:S86-S107.
15. Leimane V, Riekstina V, Holtz TH, Zarovska E, Skripconoka V, Thorpe LE, Laserson KF, Wells CD. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet. 2005 Jan 22-28;365:318-326.
16. de Jager P, van Altena R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int J Tuberc Lung Dis. 2002 Jul;6:622-627
17. Peloquin CA, Berning SE, Nitta AT, Simone PM, Goble M, Huitt GA, Iseman MD, Cook JL, Curran-Everett D. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. Clin Infect Dis. 2004 Jun 1;38:1538-1544.
18. Trn T, Gngr G, Ozmen I, Bkbasi Y, Maden E, Biaki B, Ata.G, Sevim T, Tahaoglu K. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005 Dec;9:1373-1377.